Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I: A-II and LpA-IV particles from plasma.
Tangier disease (TD) is characterized by extremely low plasma levels of HDL, apoA-I and apoA-II due to very rapid catabolism. However, the risk of premature coronary heart disease (CHD) is not markedly increased in TD. In order to gain insight into reverse cholesterol transport in TD, we isolated LpA-I, LpA-I:A-II, LpA-II and LpA-IV particles from fasting plasma of 5 TD patients. LpA-I composition was similar to control LpA-I, but TD LpA-I had more LCAT and CETP activity (respectively, 0.35 +/- 0.14 and 0.14 +/- 0.04 mumol of cholesterol esterified/h/micrograms of protein, and 7 +/- 2.5 and 1.4 +/- 0.3 mumol of cholesteryl ester transferred/h/micrograms of protein). In contrast, TD LpA-I:A-II had abnormal composition, with a low molar ratio of apoA-I to apoA-II (0.2-1.33). In addition, LpA-I:A-II in TD contained a substantial amount of apoA-IV compared with control, making this particle an LpA-I:A-II:A-IV complex. LpA-I:A-II from normal plasma do not promote cholesterol efflux from adipocytes cells, whereas TD LpA-I:A-II:A-IV complexes promoted cholesterol efflux from these cells. Moreover LpA-I:A-II:A-IV complexes have more LCAT and CETP activity than control (respectively 1.2 +/- 0.16 and 0.05 +/- 0.01 mumol of cholesterol esterified/h/micrograms of protein and, 41 +/- 3.7 and 1 +/- 0.4 mumol of cholesteryl ester transferred/h/micrograms of protein). The LpA-II particle in TD represented in fact an LpA-II:A-IV complex (75% mol apoA-II and 22% mol apoA-IV).(ABSTRACT TRUNCATED AT 250 WORDS)
Duchateau
P
P
Institut Pasteur, INSERM U. 325, Lille, France.
Rader
D
D
Duverger
N
N
Theret
N
N
De Geitere
C
C
Brewer
H B
HB
Fruchart
J C
JC
Castro
G R
GR
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D016633:Apolipoprotein A-II / Q000032:analysis* / Q000302:isolation & purification / Q000494:pharmacology; D001054:Apolipoproteins A / Q000032:analysis* / Q000302:isolation & purification / Q000494:pharmacology; D002352:Carrier Proteins / Q000032:analysis; D002478:Cells, Cultured / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D006801:Humans; D017270:Lipoprotein(a) / Q000031:analogs & derivatives* / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology; D051379:Mice; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000032:analysis; D013631:Tangier Disease / Q000097:blood*
D016633:Apolipoprotein A-II; D001054:Apolipoproteins A; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D017270:Lipoprotein(a); C022205:apolipoprotein A-IV; C078260:lipoprotein A-I; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase